Risk factors for hearing loss in patients with cystic fibrosis

Journal of the American Academy of Audiology

Volumn 27, Issue 1, 2016, Pages 6-12

  Tarshish, Yael ^a   Huang, Lin ^a,b   Jackson, Frank I ^a   Edwards, Julianne ^a   Fligor, Brian ^a,b   Wilkins, Abigail ^a   Uluer, Ahmet ^a,b   Sawicki, Gregory ^a,b   Kenna, Margaret ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Aminoglycoside induced deafness; Aminoglycosides; Cystic fibrosis; Hearing loss; Sensorineural hearing loss

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; TOBRAMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; AUDIOMETRY; BILATERAL HEARING LOSS; CHILD; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GROUPS BY AGE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PERCEPTION DEAFNESS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; COMPLICATION; INFANT; MIDDLE AGED; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AUDIOMETRY; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HEARING LOSS, SENSORINEURAL; HUMANS; INFANT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84957097167     PISSN: 10500545     EISSN: None     Source Type: Journal    
DOI: 10.3766/jaaa.14104     Document Type: Article

References (27)

1. Agrawal Y, Platz EA, Niparko JK. (2008) Prevalence of hearing loss and differences by demographic characteristics among US adults: data from the National Health and Nutrition Examination Survey, 1999-2004. Arch Intern Med 168(14):1522-1530.
2. Al-Malky G, Suri R, Dawson SJ, Sirimanna T, Kemp D. (2011) Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: a study using extended high-frequency audiometry and distortion product otoacoustic emissions. Int J Audiol 50(2):112-122.
3. Al-Malky G, Dawson SJ, Sirimanna T, Bagkeris E, Suri R. (2014) High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis. J Cyst Fibros 14(2):248-254.
4. Balogh D, Kittinger E, Benzer A, Hackl JM. (1993) Noise in the ICU. Intensive Care Med 19(6):343-346.
5. Boucher RC. (2004) New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 23(1):146-158.
6. Boulet SL, Boyle CA, Schieve LA. (2009) Health care use and health and functional impact of developmental disabilities among US children, 1997-2005. Arch Pediatr Adolesc Med 163:19-26.
7. Brummett RE. (1980) Drug-induced ototoxicity. Drugs 19(6):412-428.
8. Cheng AG, Johnston PR, Luz J, Uluer A, Fligor B, Licameli GR, Kenna MA, Jones DT. (2009) Sensorineural hearing loss inpatients with cystic fibrosis. Otolaryngol Head Neck Surg 141(1):86-90.
9. Cystic Fibrosis Foundation. (2014) CF Care Guidelines-Cystic Fibrosis Foundation http://www.cff.org/treatments/cfcareguidelines/. Accessed September 25, 2014.
10. Elborn JS, Shale DJ, Britton JR. (1991) Cystic fibrosis: current survival and population estimates for the year 2000. Thorax 46:881-885.
11. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC; Clinical Practice Guidelines for Pulmonary Therapies Committee. (2009) Cystic fibrosis pulmonary guidelines treatment of pulmonary exacerbations. Am J Respir Crit Care Med 180:802-808.
12. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Jr, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, Hazle L, Sabadosa K, Marshall B; Cystic Fibrosis Foundation, Pulmonary Therapies Committee. (2007) Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 176(10):957-969.
13. Li H, Steyger PS. (2009) Synergistic ototoxicity due to noise exposure and aminoglycoside antibiotics. Noise Health 11(42):26-32.
14. Lyczak JB, Cannon CL, Pier GB. (2002) Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15(2):194-222.
15. Martins LM, Camargos PA, Becker HM, Becker CG, Guimarães RE. (2010) Hearing loss in cystic fibrosis. Int J Pediatr Otorhinolaryngol 74(5):469-473.
16. Mogayzel PJ, Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, Lubsch L, Hazle L, Sabadosa K, Marshall B; Pulmonary Clinical Practice Guidelines Committee. (2013) Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 187(7):680-689.
17. Mulheran M, Degg C, Burr S, Morgan DW, Stableforth DE. (2001) Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Antimicrob Agents Chemother 45(9):2502-2509.
18. Piltcher OB, Teixeira VN, de Oliveira MW, Scattolin I, Piltcher SL. (2003) The prevalence of neurosensorial hearing loss among cystic fibrosis patients from Hospital de Clínicas de Porto Alegre. Int J Pediatr Otorhinolaryngol 67(9):939-941.
19. Saiman L. (2004) The use of macrolide antibiotics in patients with cystic fibrosis. Curr Opin Pulm Med 10(6):515-523.
20. Scheenstra RJ, Heijerman HG, Zuur CL, Touw DJ, Rijntjes E. (2010) No hearing loss after repeated courses of tobramycin in cystic fibrosis patients. Acta Otolaryngol 130(2):253-258.
21. Selimoglu E. (2007) Aminoglycoside-induced ototoxicity. Curr Pharm Des 13(1):119-126.
22. Shargorodsky J, Curhan SG, Curhan GC, Eavey R. (2010) Change in prevalence of hearing loss in US adolescents. JAMA 304(7):772-778.
23. Simons KS, Park M, Kohlrausch A, van den Boogaard M, Pickkers P, de Bruijn W, de Jager CP. (2014) (Noise pollution in the ICU: time to look into the mirror. Crit Care 18(4):493.
24. Smyth A, Knox A. (2011) Twice vs three times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. J Cyst Fibros 10(5):383.
25. Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, Prof Knox A; TOPIC Study Group. (2005) Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 365(9459):573-578.
26. Smyth AR, Bhatt J. (2012) Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2: CD002009.
27. Tan KH, Mulheran M, Knox AJ, Smyth AR. (2003) Aminoglycoside prescribing and surveillance in cystic fibrosis. Am J Respir Crit Care Med 167(6):819-823.